About the event

Delivered digitally to help manage travel and physical distancing restrictions, the organising committee for 6th BDP China is delighted to present an innovative and creative format for the event.

Repurposed to address the emerging and likely permanent shifts in the Chinese biopharma industry, key leaders in the region will convene online to discuss investment climate beyond 2020, technological advancements, industry case studies, and partnerships and expansion opportunities across key value chains.

With live-streaming sessions, smart networking windows and elevated exhibition platforms at our virtual BDP China, join us as the industry convenes at this highly anticipated annual gathering of biopharma leaders.

AGENDA AT-A-GLANCE

Tue, 3 November 2020
Day 1 of Main Conference
KEYNOTE ADDRESS
China’s Big Leap Towards BioPharma 2030 – Innovation, Industrialization, Internationalization
China’s Biological Facilities for the Future – WuXi’s Story on Technology & Innovation
  • Biomanufacturing 2030 – the hottest shifts in manufacturing in China
  • Trends in Pharma 4.0 standards and China’s new drug delivery strategy
  • Industry case studies for commercial manufacturing
  • The state-of-play for cell line development
  • Applications for furthering biopharma R&D strategy
  • Novel CLD platform technologies and tools
  • Industry case studies for high-throughput screening and performance
  • Maneuvering the Chinese Market for Cell and Gene Therapies
  • Addressing the next wave of innovations in cell therapies
Wed, 4 November 2020
Day 2 of Main Conference
Manufacturers’ Panel:
New Therapies, New Tech & New Investments
  • Smarty biomanufacturing and process optimization
  • Manufacturing technology showcases – Improving cost and efficiency
  • Innovative bioprocess development
  • Sustainable manufacturing and scalability
  • Advancements in cell engineering techniques for complex proteins
  • CRISPR and genomics in focus
  • Data-driven, accelerated, and next-generation CLD
  • Industry Panel: Perspectives on utilising platform technologies for CLD
  • Managing cost and accelerating manufacturing process
  • Latest CAR T-cell technology developments
  • Facilities design and construction call therapies
Wed, 5 November 2020
Day 3 of Main Conference
KEYNOTE ADDRESS
China’s Biopharma Capital Markets – Future Funds & Innovative Financing

Venture Capitals Roundtable: Show Me the Drug

  • DAL’s New GAMP and Licensing Law – Implementation and oversight
  • QbD and Quality Matrix for meeting regulatory requirements
  • Biomanufacturing process validation and quality risk management
  • Best practices and strategies in biopharma supply chain integration
  • Optimising workflows and bioprocesses
  • Exploring the synergies between engineered host cells and process development for commercial success
  • Industry Panel: what’s next in the future of CLD&E
  • Investment and commercialisation landscape
  • Case studies on clinical trial landscapes and efficacy evidence